Evidence map›Paper›PMID 42306512›Full record

ArticleIranian journal of microbiology2026

Shadi Moradi, Reza Moradi-Hajidavaloo, Fatemeh Soleimanifar, Kiana Shahzamani, Mehdi Hajian, Hajar-Alsadat Mansouri-Tehrani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shadi MoradiDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Reza Moradi-HajidavalooDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Fatemeh SoleimanifarDepartment of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Kiana ShahzamaniHepatitis Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Mehdi HajianDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Hajar-Alsadat Mansouri-TehraniDepartment of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: This study aimed to evaluate the anticancer potential of Materials and Methods: PANC-1 cancer cells and adult human dermal fibroblast (HDFa) cells were treated with various concentrations of individual or combined CFSs. Cell viability was assessed using the MTT assay. Apoptosis was evaluated through Hoechst/PI staining and flow cytometry, while cell cycle distribution was analyzed via flow cytometry. Gene expression of Results: At 20% (v/v), all CFS treatments significantly reduced PANC-1 cell viability while showing minimal effects on HDFa cells. Flow cytometry confirmed apoptotic rates of 39.33%, 42%, and 40.33% for Conclusion: CFSs from

Indexed as

BAXBCL-XLLacticaseibacillus caseiLacticaseibacillus rhamnosusPancreatic cancer

Identifiers

PMID42306512
PMCPMC13265972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.